Emerging Strategies in TCR-Engineered T Cells

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Adoptive cell transfer (ACT) immunotherapies, including CAR-T and TCR-T, have advanced cancer treatment.
• TCR-T cells recognize intracellular and cell-surface tumor antigens, including neoantigens, at lower concentrations than CAR-T cells.

Purpose of the Study:

• To review current challenges and opportunities in TCR-T therapy.
• To outline strategies for improving TCR-T efficacy, particularly for solid tumors.

Main Methods:

• Review of basic, translational, and clinical research on TCR-T therapy.
• Analysis of emerging ACT strategies and limitations.
• Proposal of a combination therapy approach.

Main Results:

• TCR-T therapy offers potential for treating various human cancers due to its sensitivity and broad target recognition.
• Targeting tumor-specific neoantigens is crucial for effective cancer immunotherapy.
• A combination strategy involving neoantigen vaccines, checkpoint blockade, and neoantigen-specific TCR-T is proposed.

Conclusions:

• TCR-T therapy holds significant promise for cancer treatment, especially for solid tumors.
• Combining neoantigen vaccines, checkpoint blockade, and TCR-T offers a potential strategy for a tumor-specific therapy.
• This integrated approach may improve cancer immunotherapy outcomes and provide a general strategy for eradicating multiple cancers.